CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MedReleaf Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MedReleaf Corp
Markham Industrial Park
PO Box 3040
Phone: (289) 317-1004p:289 317-1004 MARKHAM, ON  L3R 6G4  Canada
This company was Merged or Acquired on 7/25/2018.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
MedReleaf Corp is a Canada-based company which operates as a licensed producer of cannabis-based pharmaceutical products. The Company produces and sells its dried cannabis and cannabis oil products, including cannabis oil capsules. The Company produce an aggregate of up to 6,000 kilograms of dried cannabis and up to 1,760 kilograms of cannabis oil, and to sell and distribute within Canada an aggregate of up to 5,000 kilograms of dried cannabis, up to 1,319 kilograms of bottled cannabis oil, and up to 440 kilograms of encapsulated cannabis oil. The Company is an analytically-driven organization focused on patient care, scientific innovation, and advancing the understanding of the therapeutic benefits of cannabis.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20183/31/2018Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President EitanPopper 35
Interim Chief Executive Officer AllanCleiren 7/25/2018 7/25/2018
Chief Financial Officer, Corporate Secretary IgorGimelshtein
6 additional Officers and Directors records available in full report.

Business Names
Business Name
LEAF
MED Colombia SAS

General Information
Stock Exchange: TSE


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023